This program was possible with support from Bayer.
Alicia Morgans, MD, MPH, reviews the incidence of prostate cancer and risk factors associated with the disease.
The Prostate Cancer Treatment Landscape
This program was possible with support from Bayer.
Clinical insights on the typical presentation of prostate cancer and how the disease is diagnosed.
This program was possible with support from Bayer.
Reginald Tucker-Seeley, MA, ScM, ScD, gives an overview of the screening and diagnosis process of prostate cancer.
This program was possible with support from Bayer.
Rashid K. Sayyid, MD, MSc, describes the staging and risk stratification process for patients with prostate cancer and their effect on prognosis.
This program was possible with support from Bayer.
An experienced public health and cancer researcher offers advice to patients newly diagnosed with prostate cancer and discusses barriers to access to care.
This program was possible with support from Bayer.
A genitourinary oncologist provides insights on the treatment decision-making process and the roles of guidelines for prostate cancer.
This program was possible with support from Bayer.
Expert perspectives on how clinical trials and real-world evidence contribute to treatment decisions in prostate cancer.
This program was possible with support from Bayer.
A urologic oncology fellow provides a comprehensive overview of systemic therapy options for patients with prostate cancer.
This program was possible with support from Bayer.
Alicia Morgans, MD, MPH, discusses androgen deprivation therapy and its role in treating prostate cancer.
This program was possible with support from Bayer.
A comprehensive review of treatment options for patients with metastatic hormone-sensitive prostate cancer.
This program was possible with support from Bayer.
An expert on prostate cancer gives a brief overview of castrate-resistant prostate cancer.
This program was possible with support from Bayer.
Rashid K. Sayyid, MD, MSc, gives a brief overview of treatment options for nonmetastatic castrate-resistant prostate cancer.
This program was possible with support from Bayer.
Expert perspectives on the treatment approach for patients with metastatic castrate-resistant prostate cancer.
This program was possible with support from Bayer.
Rashid K. Sayyid, MD, MSc, discusses the role of combination therapy in metastatic castrate-resistant prostate cancer.
This program was possible with support from Bayer.
Practical advice for improving clinical trials to ensure they are more reflective of the overall population of patients with prostate cancer.
This program was possible with support from Bayer.
Alicia Morgans, MD, MPH, offers advice to patients newly diagnosed with prostate cancer and reviews educational resources available for patients and their caregivers.
This program was possible with support from Bayer.
Reginald Tucker-Seeley, MA, ScM, ScD, concludes the program with advice for caregivers and patients with prostate cancer to maximize the benefit of treatment.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Welireg Plus Keytruda Combination for Adjuvant Treatment of Renal Cell Carcinoma
2
A CAR-T Therapy Is Working Better Than Expected for Patients With Hard to Treat Leukemia
3
Your Tumor's Genetic Profile May Not Change Which Treatment Works Best for TNBC
4
From "Not Curable" to "May Be Curable": Joshua Richter, MD, on the New Reality of Multiple Myeloma
5